GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (LSE:HCM) » Definitions » Insider Ownership

HUTCHMED (China) (LSE:HCM) Insider Ownership : 2.77 % (As of Dec. 15, 2024)


View and export this data going back to 2006. Start your Free Trial

What is HUTCHMED (China) Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, HUTCHMED (China)'s insider ownership is 2.77%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, HUTCHMED (China)'s Institutional Ownership is 21.23%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, HUTCHMED (China)'s Float Percentage Of Total Shares Outstanding is 59.66%.


HUTCHMED (China) Insider Ownership Historical Data

The historical data trend for HUTCHMED (China)'s Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) Insider Ownership Chart

HUTCHMED (China) Historical Data

The historical data trend for HUTCHMED (China) can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Insider Ownership 2.56 2.80 2.77 2.77 2.77 2.77 2.77 2.77 2.77 2.77

HUTCHMED (China) Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


HUTCHMED (China) Business Description

Address
2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.